Literature DB >> 1379149

Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity.

D McTavish1, R C Heel.   

Abstract

Dexfenfluramine stimulates serotoninergic activity by inhibiting serotonin reuptake into presynaptic neurons and by enhancing its release into brain synapses. Based on the serotonin hypothesis of appetite control these effects would be expected to reduce food intake and thus body-weight. Studies in animal models and severely overweight patients have confirmed the effectiveness of dexfenfluramine as a weight-reducing agent which appears to be well tolerated. Permanent weight loss is the goal of weight-reducing strategies and, based on current clinical evidence, dexfenfluramine appears to exert a weight reducing effect over periods of up to 12 months without development of tolerance, a problem that has limited the long term use of other pharmacological agents used in the treatment of this disorder. Dexfenfluramine facilitated weight loss in patients who had not responded satisfactorily to other weight-reducing strategies, prevented relapse in those patients who had achieved weight reduction by other methods, and corrected disturbed eating patterns (and therefore reduced weight gain) in small studies involving patients with premenstrual syndrome, seasonal affective disorder and nicotine withdrawal syndrome. Follow-up of the longest study reported with dexfenfluramine suggests that continued therapy is required in severely overweight patients if weight loss is to be maintained. Dexfenfluramine has not been directly compared with nonpharmacological measures of weight control such as behaviour modification or exercise programmes. The decision that pharmacological means are indicated in overweight patients must be highly individualised, and must consider the many complex factors that often contribute to overweight states, as well as the anticipated magnitude of drug effect. Despite such a cautionary note, and the expected need (at this stage of its development) for an expanded clinical study programme in certain areas, dexfenfluramine is a clear advance in the pharmacological approach to improved management of overweight individuals.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379149     DOI: 10.2165/00003495-199243050-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  70 in total

1.  Drugs that enhance central serotoninergic transmission diminish elective carbohydrate consumption by rats.

Authors:  J J Wurtman; R J Wurtman
Journal:  Life Sci       Date:  1979-03-05       Impact factor: 5.037

2.  Permanent administration of d-fenfluramine in rats: paradoxical effects.

Authors:  R Rozen; F Fumeron; D Betoulle; F Baigts; A Mandenoff; J Fricker; M Apfelbaum
Journal:  Clin Neuropharmacol       Date:  1988       Impact factor: 1.592

Review 3.  Carbohydrate craving. Relationship between carbohydrate intake and disorders of mood.

Authors:  J J Wurtman
Journal:  Drugs       Date:  1990       Impact factor: 9.546

4.  Fenfluramine administered systemically or locally increases extracellular serotonin in the lateral hypothalamus as measured by microdialysis.

Authors:  D Schwartz; L Hernandez; B G Hoebel
Journal:  Brain Res       Date:  1989-03-20       Impact factor: 3.252

Review 5.  Serotonin manipulations and the structure of feeding behaviour.

Authors:  J E Blundell
Journal:  Appetite       Date:  1986       Impact factor: 3.868

Review 6.  Progress in assessing the role of serotonin in the control of food intake.

Authors:  S Garattini; A Bizzi; S Caccia; T Mennini; R Samanin
Journal:  Clin Neuropharmacol       Date:  1988       Impact factor: 1.592

7.  The interaction of metergoline, a 5-HT receptor blocker, and dexfenfluramine in human feeding.

Authors:  E Goodall; T Silverstone
Journal:  Clin Neuropharmacol       Date:  1988       Impact factor: 1.592

8.  d-Fenfluramine selectively decreases carbohydrate but not protein intake in obese subjects.

Authors:  J J Wurtman; R J Wurtman
Journal:  Int J Obes       Date:  1984

9.  Effect of dexfenfluramine on body weight set-point: study in the rat with hoarding behaviour.

Authors:  M Fantino; F Faion; Y Rolland
Journal:  Appetite       Date:  1986       Impact factor: 3.868

10.  Effect of D-fenfluramine on serotonin release in brains of anaesthetized rats.

Authors:  B Laferrere; R J Wurtman
Journal:  Brain Res       Date:  1989-12-18       Impact factor: 3.252

View more
  13 in total

Review 1.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Outcomes of pharmacological and surgical treatment for obesity.

Authors:  J Cerulli; M Malone
Journal:  Pharmacoeconomics       Date:  1998-09       Impact factor: 4.981

3.  Sertraline enhances the effects of cognitive-behavioral treatment on weight reduction of obese patients.

Authors:  V Ricca; E Mannucci; M Di Bernardo; S M Rizzello; P L Cabras; C M Rotella
Journal:  J Endocrinol Invest       Date:  1996-12       Impact factor: 4.256

Review 4.  Current concepts in the pharmacological management of obesity.

Authors:  P J Carek; L M Dickerson
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

Review 5.  Bodyweight change as an adverse effect of drug treatment. Mechanisms and management.

Authors:  H Pijl; A E Meinders
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

6.  Acute tryptophan depletion and sweet food consumption by overweight adults.

Authors:  Sherry L Pagoto; Bonnie Spring; Dennis McChargue; Brian Hitsman; Malaina Smith; Bradley Appelhans; Donald Hedeker
Journal:  Eat Behav       Date:  2008-10-30

Review 7.  Appetite suppressants. A review.

Authors:  T Silverstone
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

8.  Anorectic effect and brain concentrations of D-fenfluramine in the marmoset: relationship to the in vivo and in vitro effects on serotonergic mechanisms.

Authors:  S Caccia; M Anelli; C Fracasso; E Frittoli; P Giorcelli; M Gobbi; C Taddei; S Garattini; T Mennini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-03       Impact factor: 3.000

9.  Functional consequences of central serotonin depletion produced by repeated fenfluramine administration in rats.

Authors:  M H Baumann; M A Ayestas; R B Rothman
Journal:  J Neurosci       Date:  1998-11-01       Impact factor: 6.167

10.  The pharmacokinetics of dexfenfluramine in obese and non-obese subjects.

Authors:  G Cheymol; J Weissenburger; J M Poirier; C Gellee
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.